跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 40,917 条关于
“Akeso Inc.”
全部
40,917
临床试验
11,202
药物
1,601
机构
6,170
资讯
21,944
去年
Akeso's Phase 3 Trial Begins for Ivonescimab and Ligufalimab Combination in Head and Neck Cancer
去年
First-in-Class IL-4Rα/ST2 Bispecific Antibody AK139 Advances to Clinical Development for Inflammatory Diseases
去年
Akeso Completes Patient Enrollment in Phase III Trial Comparing Ivonescimab for First-Line Squamous NSCLC Treatment
去年
China's NMPA Accepts NDAs for Lung and Liver Cancer Therapies
2年前
Akeso Initiates Phase III Trial of Cadonilimab Bispecific Antibody for PD-L1 Negative NSCLC
10个月前
Akeso's AK135 Shows Promise for Chemotherapy-Induced Neuropathy in Preclinical Studies
2年前
Akeso's Bispecific Antibodies Show Promise in Lung and Colorectal Cancers
2年前
Ivonescimab Monotherapy Shows Significant PFS Improvement in NSCLC
去年
Cadonilimab Plus Chemotherapy Shows Survival Benefit in Advanced Gastric Cancer
去年
Summit Therapeutics' Ivonescimab Shows Promise in NSCLC Trials
第 1 页,共 2195 页
上一页
下一页